TERISA was sponsored by Gilead Sciences. Dr. Kosiborod reported serving as a consultant to Gilead and several other pharmaceutical and medical device companies. Dr. Gibson reported having financial ties to numerous pharmaceutical and device manufacturers, but not Gilead. Dr. Quinones reported having no relevant industry relationships.
Conference Coverage
TERISA targets diabetes as potential new market for ranolazine
Publish date: March 15, 2013
AT ACC 13